Aarey Drugs & Pharmaceuticals Ltd Stock Price Today (NSE: AAREYDRUGS)
Fundamental Score
Aarey Drugs & Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aarey Drugs & Pharmaceuticals Ltd share price today is ₹75.60, down 2.29% on NSE/BSE as of 22 June 2026. Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹245.46 (Cr). The 52-week high for AAREYDRUGS share price is ₹100.00 and the 52-week low is ₹50.31. At a P/E ratio of 68.56x, AAREYDRUGS is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 2.96% and a debt-to-equity ratio of 0.34.
Aarey Drugs & Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Aarey Drugs & Pharmaceuticals Ltd share price chart: -12.82% return over the past month. 52-week high ₹100.00, 52-week low ₹50.31.
Aarey Drugs & Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹78.92 | ₹78.92 | ₹74.60 | ₹75.60 | 35.80K (Cr) | |
| ₹77.99 | ₹81.00 | ₹76.00 | ₹77.37 | 51.46K (Cr) | |
| ₹79.73 | ₹80.00 | ₹76.30 | ₹77.99 | 7.14K (Cr) | |
| ₹79.75 | ₹81.48 | ₹76.56 | ₹79.73 | 38.02K (Cr) | |
| ₹82.94 | ₹82.94 | ₹79.11 | ₹79.74 | 10.66K (Cr) | |
| ₹83.73 | ₹83.73 | ₹81.50 | ₹81.84 | 8.03K (Cr) | |
| ₹82.53 | ₹85.00 | ₹78.30 | ₹83.74 | 80.33K (Cr) | |
| ₹85.00 | ₹85.99 | ₹81.30 | ₹82.03 | 20.49K (Cr) | |
| ₹82.60 | ₹86.90 | ₹81.12 | ₹85.06 | 81.78K (Cr) | |
| ₹87.11 | ₹87.11 | ₹84.60 | ₹85.38 | 50.78K (Cr) |
Aarey Drugs & Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹77.99 | ₹81.00 | ₹74.60 | ₹75.60 | -3.06% | |
| ₹90.99 | ₹92.50 | ₹76.30 | ₹77.99 | -14.29% | |
| ₹52.99 | ₹96.00 | ₹52.28 | ₹91.08 | +71.88% | |
| ₹74.94 | ₹75.00 | ₹50.31 | ₹50.75 | -32.28% | |
| ₹64.22 | ₹86.37 | ₹61.08 | ₹76.73 | +19.48% | |
| ₹68.87 | ₹73.00 | ₹60.54 | ₹67.60 | -1.84% | |
| ₹87.40 | ₹87.40 | ₹62.50 | ₹67.67 | -22.57% | |
| ₹96.25 | ₹100.00 | ₹83.78 | ₹87.69 | -8.89% | |
| ₹83.90 | ₹94.97 | ₹79.71 | ₹94.97 | +13.19% | |
| ₹60.10 | ₹83.50 | ₹60.10 | ₹82.84 | +37.84% | |
| ₹66.95 | ₹72.00 | ₹57.50 | ₹60.16 | -10.14% | |
| ₹69.36 | ₹72.42 | ₹62.00 | ₹65.64 | -5.36% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Aarey Drugs is a fundamentally weak micro-cap being driven by pure speculation; a short is brewing.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Aarey Drugs locked at its upper circuit of 5.0% on April 15, 2026. MarketsMojo downgraded the stock to Strong Sell as of November 28, 2025, but it has shown resilience, gaining 3.06% on the day of the circuit hit.
CORE STORY (THE REAL GAME)
This is a micro-cap momentum play fueled by speculative buying, detached from underlying fundamentals. The market is ignoring deteriorating financials and focusing on price action.
- Upper circuit momentum
- Increase in delivery volume
- Technical breakout
- Positive news flow in the pharma sector
- A large order win
- Improved quarterly results
- Micro/SME cap = liquidity risk
- Deteriorating financials: Q3FY26 revenue and profit down
- Rated Strong Sell by MarketsMojo
FII increased holdings from 1.13% to 3.86% in Dec 2025, while Promoters decreased holdings from 44.80% to 39.06% in Dec 2025.
Indian pharma sector is seeing increased investment, but Aarey Drugs is not positioned to benefit.
No: Free Cash Flow 5Y is ₹-0.03 Cr
Short-term momentum may continue, but the long-term outlook is bleak due to weak fundamentals. Expect a sharp correction.
Primary Thesis Risk
The biggest thesis killer is continued speculative buying overriding fundamental weakness.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Aarey Drugs & Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aarey Drugs & Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AAREYDRUGS across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
12 factors identified
Below-Average Return on Equity (2.96%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.38%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (1.46%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 68.56x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-36.25%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-19.95%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-10.55% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-7.04% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (2.49x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-0.03 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 1.13%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Aarey Drugs & Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Aarey Drugs & Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Aarey Drugs & Pharmaceuticals LtdAarey Drugs & P...Selected✓ AAREYDRUGS • 524412 | 17.4/100 | ₹75.60₹76 | ₹245.46₹245.46 | 68.56Average 68.6 Average | 2.96%Poor 2.96% Poor | 6.38%Poor 6.38% Poor | 0.34Excellent 0.3 Excellent | -7.04%Poor -7.04% Poor | 9.76%Good 9.76% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Aarey Drugs & Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for AAREYDRUGS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹1.43 | ₹67.67 | 47.3x |
| FY 2024 | ₹1.84 | ₹57.10 | 31x |
| FY 2023 | ₹1.49 | ₹50.55 | 33.9x |
| FY 2022 | ₹2.72 | ₹38.65 | 14.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Aarey Drugs & Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for AAREYDRUGS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-19.95%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-36.25%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.76%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-7.04%
Compounded annual net profit growth over 5 years
Aarey Drugs & Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AAREYDRUGS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Aarey Drugs & Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Aarey Drugs & Pharmaceuticals Ltd
About AAREYDRUGS (Aarey Drugs & Pharmaceuticals Ltd)
Aarey Drugs & Pharmaceuticals Ltd is a dynamic player in the pharmaceutical landscape, dedicated to the meticulous crafting of vital chemical components. The company specializes in... the production of high-quality active pharmaceutical ingredients (APIs), catering to a diverse range of therapeutic needs. Beyond APIs, Aarey Drugs distinguishes itself through its expertise in manufacturing sophisticated pharmaceutical intermediates. These carefully synthesized compounds serve as crucial building blocks, enabling the efficient creation of complex drug formulations. A commitment to precision and purity permeates every stage of the manufacturing process, ensuring that the final products meet the stringent demands of the healthcare industry and contribute to improved patient outcomes. Aarey Drugs's product portfolio showcases a balance between established pharmaceutical staples and innovative specialty chemicals. The company offers a selection of essential intermediates, including components used in synthesizing various medications and treatments. These intermediates, produced with rigorous quality control measures, empower pharmaceutical manufacturers to streamline their own production processes. Furthermore, Aarey Drugs is a reliable source for critical APIs, with a focus on producing ingredients that address widespread health concerns. By combining both intermediate and API production, the company positions itself as a comprehensive supplier to the pharmaceutical sector, capable of meeting diverse requirements and supporting the development of a wide array of medications. Supplementing its core manufacturing activities, Aarey Drugs also engages in the responsible trading of essential chemicals and solvents. This division acts as a vital resource for pharmaceutical and chemical companies seeking reliable access to quality materials. A commitment to ethical sourcing and responsible distribution practices underpins this aspect of the company's operations. By maintaining strong relationships with suppliers and adhering to stringent safety standards, Aarey Drugs facilitates the seamless flow of necessary components throughout the industry. This multifaceted approach, encompassing manufacturing and responsible trading, reinforces Aarey Drugs' commitment to supporting the entire pharmaceutical ecosystem.
Company Details
Key Leadership
AAREYDRUGS Share Price: Frequently Asked Questions
What is the current share price of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) trades at ₹75.60 on NSE and BSE. Market cap ₹245.46 (Cr). Educational data only.
What is the P/E ratio of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd has a P/E of 68.56x vs industry average 31.77x.
What is the Bull Run score for Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd has a Bull Run score of 17.4/100 based on 25+ financial parameters.
Does Aarey Drugs & Pharmaceuticals Ltd pay dividends?
Aarey Drugs & Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd has ROE of 2.96%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd has debt-to-equity of 0.34.
Is Aarey Drugs & Pharmaceuticals Ltd a good investment?
Bull Run gives Aarey Drugs & Pharmaceuticals Ltd a score of 17.4/100. This is not investment advice — consult a SEBI-registered advisor.